Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

New long-term data highlights the effectiveness and safety of ivosidenib plus azacitidine for treating IDH1-mutated acute myeloid leukemia in vulnerable patients.

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

The FDA approved multiple groundbreaking treatments in July, enhancing options across patient populations.

Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.